Cost-effectiveness of treatments reducing coronary heart disease mortality in Ireland, 2000 to 2010.
AffiliationDepartment of Pharmacology and Therapeutics, Trinity Centre for Health Sciences, St James's Hospital, Dublin, Ireland. email@example.com
MetadataShow full item record
CitationCost-effectiveness of treatments reducing coronary heart disease mortality in Ireland, 2000 to 2010. 2009, 12 (1):10-5notValue Health
JournalValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
AbstractOBJECTIVE: Coronary heart disease (CHD) is associated with a large burden of disease in Ireland and is responsible for more than 6000 deaths annually. This study examined the cost-effectiveness of specific CHD treatments in Ireland. METHODS: Irish epidemiological data on patient numbers and median survival in specific groups, plus the uptake, effectiveness, and costs of specific interventions, all stratified by age and sex, were incorporated into a previously validated CHD mortality model, the IMPACT model. This model calculates the number of life-years gained (LYGs) by specific cardiology interventions to generate incremental cost-effectiveness ratios (ICERs) per LYG for each intervention. RESULTS: In 2000, medical and surgical treatments together prevented or postponed approximately 1885 CHD deaths in patients aged 25 to 84 years, and thus generated approximately 14,505 extra life-years (minimum 7270, maximum 22,475). In general, all the cardiac interventions investigated were highly cost-effective in the Irish setting. Aspirin, beta-blockers, ACE inhibitors, spironolactone, and warfarin for specific conditions were the most cost-effective interventions (< euro 3000/LYG), followed by the statins for secondary prevention (< euro 6500/LYG). Revascularization for chronic angina and primary angioplasty for myocardial infarction, although still cost-effective, had the highest ICER (between euro 12,000 and euro 20,000/LYG). CONCLUSIONS: Using a comprehensive standardized methodology, cost-effectiveness ratios in this study clearly favored simple medical treatments for myocardial infarction, secondary prevention, angina, and heart failure.
- Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.
- Authors: Fidan D, Unal B, Critchley J, Capewell S
- Issue date: 2007 May
- The population mortality benefits of maximizing the number of eligible patients receiving appropriate cardiology treatments in Ireland.
- Authors: Kabir Z, Bennett K, Shelley E, Unal B, Critchley J, Feely J, Capewell S
- Issue date: 2006 Aug
- Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
- Authors: Zhang Z, Mahoney EM, Kolm P, Spertus J, Caro J, Willke R, Weintraub WS
- Issue date: 2010
- Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.
- Authors: Peura P, Martikainen J, Soini E, Hallinen T, Niskanen L
- Issue date: 2008 Jun
- A systematic review and economic evaluation of statins for the prevention of coronary events.
- Authors: Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N
- Issue date: 2007 Apr